JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Acute Leukoencephalopathies:Differential Diagnosis and Investigation
The Neurologist 4:148-166, Weinshenker,B.G.,et al, 1998
Herpes Simplex Virus in Postmortem Multiple Sclerosis Brain Tissue
Arch Neurol 53:125-133, 1231996., Sanders,V.J.,et al, 1996
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Numb Chin Syndrome
UptoDate.com Sept, Robertson, C.E., 2018
Reactivation of Herpesvirus under Fingolimod: A Case of Severe Herpes Simplex Encephalitis
Neurol 84:2377-2378, Pfender, N.,et al, 2015
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Herpes Encephalitis During Natalizumab Tretament in Multiple Sclerosis
Mult Scler J 18:909-911, Kwiatkowski, A.,et al, 2012
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008
An Approach to the Diagnosis of Acute Transverse Myelitis
Semin Neurol 28:105-120, Jacob, A.,et al, 2008
Differential Diagnosis of Bilateral Thalamic Lesions
Clin Neuroradiol 17:3-22, Linn,J.,et al, 2007
Diffusion-Weighted MR Imaging of the Brain
Radiology 217:331-345, Schaefer,P.W.,et al, 2000
Subacute Leukoencephalitis Caused by CNS Infection with Human Herpesvirus-6 Manifesting as Acute Multiple Sclerosis
Neurol 47:145-148, Carrigan,D.R.,et al, 1996
Cerebrospinal Fluid
JNNP 59:349-357, Thompson,E.J., 1995
Retroviruses and Multiple Sclerosis. I. Analysis of Seroreactivity by Western Blot and Radioimmune Assay
Neurol 40:1251-1253, Weinshenker,B.G.,et al, 1990
Retroviruses & Multiple Sclerosis. II. Failure of Gene Amplification Techniques to Detect Viral Sequences
Neurol 40:1254-1258, Dekaban,G.A.&Rice,G.P.A., 1990
Isolation of Herpes Simplex Virus Type 1 During First Attack of Multiple Sclerosis
Ann Neurol 26:283-285, Bergstrom,T.,et al, 1989
Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983
Viral Infections & Demylinating Diseases
NEJM 288:1103, Weiner,J.,et al, 1973
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
The Etiology of Ring Lesions on Diffusion-Weighted Imaging
NeuroRadiol J 27:280-287, Finelli, P. & Foxman, E.B., 2014
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
NEJM 361:1067-1074, Chen,Y.,et al, 2009
Reemergence of PML in Natalizumab-Treated Patients--New Cases, Same Concerns
NEJM 361:1041-1043, Major,E., 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
NEJM 353:375-381, Langer-Gould,A.,et al, 2005
Bacterial Infection as a Cause of Multiple Sclerosis
Lancet 360:352-353, Wolfson,C. &Talbot,P., 2002
Lesions of the Corpus Callosum: MR Imaging and Differential Considerations in Adults and Children
AJR 179:251-257, Bourekas,E.C.,et al, 2002
The Differential Diagnosis of Multiple Sclerosis
JNNP 71(suppl II):ii9-ii15, Scolding, N., 2001
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Twelfth-Nerve Palsy:Analysis of 100 Cases
Arch Neurol 53:561-566, Keane,J.R., 1996